BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio (Nasdaq: BBIO) will present two oral presentations and three posters on new acoramidis data in transthyretin amyloid cardiomyopathy (ATTR-CM) at the ESC Congress 2026 in Munich on August 28–31, 2026. These include open-label extension analyses from the ATTRibute-CM study, covering survival, hospitalization days, myocardial structure/function, and patient-reported outcomes in wild-type and variant ATTR-CM.
In partnership with Yale’s Cardiovascular Data Science Lab, three additional moderated ePosters will highlight AI-driven approaches for ATTR-CM, including a digital biomarker AI-ECG, a decentralized digital registry, and a nationwide multimodal screening network. Acoramidis is marketed as Attruby and BEYONTTRA, indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM. Diarrhea and upper abdominal pain were the most common adverse reactions versus placebo, with similar discontinuation rates.
BridgeBio Pharma (Nasdaq: BBIO) announced the pricing of a secondary offering of 5,000,000 shares of its common stock to be sold by existing shareholder KKR Genetic Disorder L.P.. BridgeBio is not issuing any shares in this transaction and will not receive any offering proceeds.
The offering is expected to close on August 17, 2026, subject to customary closing conditions. William Blair, Goldman Sachs & Co. LLC and KKR Capital Markets LLC are acting as joint book-running managers. The shares are being offered under an automatic shelf registration statement on Form S-3ASR filed with the SEC on July 24, 2026.
BridgeBio Pharma (Nasdaq: BBIO) announced the launch of a secondary public offering of 5,000,000 shares of its common stock to be sold by existing shareholder KKR Genetic Disorder L.P. The company is not selling any shares in this transaction and will not receive any proceeds.
William Blair, Goldman Sachs & Co. LLC and KKR are acting as joint book-running managers. The offering is being made under an automatic shelf registration statement on Form S-3ASR and remains subject to market and other conditions, with final terms to be disclosed in a prospectus supplement filed with the SEC.
BridgeBio Pharma (Nasdaq: BBIO) reported that on August 8, 2026, its board compensation committee approved equity inducement grants of restricted stock units to 56 new employees, covering an aggregate of 66,705 shares of common stock. One-fourth of each grant will vest on August 16, 2027, with the remaining shares vesting in equal quarterly installments thereafter, subject to continued employment. The awards were granted as inducements to employment under Nasdaq Listing Rule 5635(c)(4) and pursuant to a company plan adopted in November 2019 and amended in February and December 2023.
BridgeBio (Nasdaq: BBIO) reported second quarter 2026 total revenues of $243.7 million, including $222.4 million of U.S. Attruby net product revenue, $15.4 million of royalty revenue, and $5.8 million of license and services revenue. Growth was led by treatment‑naïve ATTR‑CM patients starting and remaining on Attruby.
According to BridgeBio, new post‑hoc analyses linked acoramidis to kidney‑protective effects and improved cardiovascular outcomes, while real‑world evidence associated Attruby with fewer cardiovascular events and hospitalizations versus tafamidis. All three planned NDAs (BBP‑418, encaleret, oral infigratinib) are now with the FDA, two under Priority Review, and the company ended the quarter with $720.2 million in cash and securities, excluding a $1 billion preferred equity financing closed July 1, 2026.
BridgeBio (Nasdaq: BBIO) announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. The company will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
According to BridgeBio, investors can access a live webcast of the presentation via the “Events & Presentations” page in the Investors section of its website, with a replay available for 30 days. Participants must register online through the provided webcast link. The company also highlights its focus on developing medicines for genetic conditions using a decentralized hub-and-spoke R&D model.
BridgeBio (Nasdaq: BBIO) announced that the FDA has accepted its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1), with a PDUFA target action date of May 8, 2027. The FDA is not currently planning an advisory committee meeting, and BridgeBio is preparing to launch encaleret upon potential approval.
The Phase 3 CALIBRATE trial in ADH1 achieved all pre-specified primary and key secondary efficacy endpoints, showing normalization of key disease markers without calcium and vitamin D supplements and a favorable safety profile. BridgeBio is enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial in pediatric ADH1, and plans to start RECLAIM-HP, a global Phase 3 trial in chronic hypoparathyroidism, later in 2026. The company also plans to submit a European MAA in the second half of 2026 and notes that over 2,100 individuals have been diagnosed with autosomal dominant hypocalcemia in the U.S. since October 2023.
BridgeBio Pharma (Nasdaq: BBIO) reported that on July 7, 2026, its board compensation committee approved inducement equity grants of restricted stock units to 37 new employees, covering an aggregate of 83,283 common shares. One-fourth vests on August 16, 2027, then quarterly, subject to continued employment, under a board-adopted equity plan.
BridgeBio Pharma (Nasdaq: BBIO) reported new post-hoc analyses of Phase 2 and Phase 3 ATTRibute-CM data showing early and sustained kidney-related effects of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM).
Acoramidis initiation showed an acute, reversible eGFR dip of 8.5 mL/min/1.73m² with a placebo-corrected 15.5% UACR reduction by Day 28 (P<0.05). Through Month 30, an improved chronic eGFR slope of +2.47 mL/min/1.73m²/year (p<0.001) and a 13.7% sustained UACR reduction (p=0.026) were observed. Participants with larger eGFR dips had a 58% lower risk of death or cardiovascular hospitalization and 66% lower risk of hospitalization alone in the first year. No kidney-related adverse events were reported in these analyses. Acoramidis is approved as Attruby in the U.S. and as BEYONTTRA in multiple global markets, with labels specifying near-complete (≥90%) TTR stabilization.
BridgeBio (Nasdaq: BBIO) entered a preferred equity agreement with funds managed by Sixth Street and HealthCare Royalty for up to $1 billion in Series A cumulative convertible participating stock.
The shares carry a 7% initial dividend and an initial conversion price of $137.79, supporting Attruby and three potential U.S. launches within 12 months.